3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
43
Phase 1
37
Phase 1/2
22
Phase NA
4
Phase EARLY_PHASE1
4
Phase 3
3
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
Recurrence
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Older Patients
1
Myasthenia Gravis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Autoimmune Diseases
1
Interventions
Cyclophosphamide
10
Etoposide
6
Doxorubicin
6
Cytarabine
6
Prednisone
5
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Methotrexate
4
gamma-Globulins
3
Rituximab
3
Radiotherapy
3
Filgrastim
3
Ciprofloxacin
3
pegaspargase
2
nelarabine
2
etoposide phosphate
2
calaspargase pegol
2
Triptorelin Pamoate
2
Thioguanine
2
Prednisolone
2
Methylprednisolone
2
Mercaptopurine
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Immunoglobulins, Intravenous
2
Dexamethasone
2
Daunorubicin
2
Cyclosporine
2
Calcium Dobesilate
2
Bortezomib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma
×
fludarabine
×
Clear all
NCT00641095
2018-10-31
MCLPIII
University College, London
Phase 2/3
Completed
370 enrolled